The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tassi, I.
Right arrow Articles by Colonna, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tassi, I.
Right arrow Articles by Colonna, M.
The Journal of Immunology, 2005, 175: 7996-8002.
Copyright © 2005 by The American Association of Immunologists

The Cytotoxicity Receptor CRACC (CS-1) Recruits EAT-2 and Activates the PI3K and Phospholipase C{gamma} Signaling Pathways in Human NK Cells1

Ilaria Tassi and Marco Colonna2

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The CD2-like receptor-activating cytotoxic cell (CRACC) is a cell surface receptor of the CD2 family that triggers NK cell-mediated cytotoxicity through an undefined signaling pathway. CRACC contains cytoplasmic tyrosine-based motifs, immunoreceptor tyrosine-based switch motifs, which resemble those found in the NK cell receptor 2B4. In 2B4, these motifs recruit the adaptor signaling lymphocytic activation molecule-associated protein (SAP), which initiates a signaling cascade mediating cytotoxicity. However, CRACC does not recruit SAP. In this study, we demonstrate that, upon activation, CRACC associates with a homolog of SAP, Ewing’s sarcoma’s/FLI1-activated transcript 2 (EAT-2), in human NK cells. We show that association of EAT-2 induces the phosphorylation of CRACC and that this process is partially reduced by a pharmacological inhibitor of Src kinases. We identify PLC{gamma}1, PLC{gamma}2, and PI3K as the major signaling mediators downstream of CRACC/EAT-2 implicated in NK cell-mediated cytotoxicity. Moreover, EAT-2 also associates with 2B4 predominantly in resting NK cells, whereas SAP preferentially binds 2B4 upon activation. These results outline a new signaling pathway that triggers CRACC-mediated cytotoxicity and modulates 2B4-mediated activation.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Natural killer cells express a broad repertoire of activating receptors that trigger multiple signaling pathways leading to cytotoxicity and secretion of IFN-{gamma} (1, 2, 3, 4). Among these are a growing number of cell surface members of the Ig superfamily homologous to CD2, including CD2, CD48, CD58, signaling lymphocytic activation molecule (SLAM)3 (CD150), 2B4 (CD244), CD84, Ly-9 (CD229), NK-T-B-Ag (NTB-A), CD2-like receptor-activating cytotoxic cell (CRACC), and B lymphocyte activator macrophage expressed (BLAME) (5, 6, 7). These receptors mediate either homophilic adhesion or heterophilic interactions with other CD2 family members. The cytoplasmic domains of SLAM, 2B4, CD84, Ly-9, CRACC, and NTB-A contain unique amino acid motifs, TxYxxV/I, called immunoreceptor tyrosine-based switch motifs (ITSMs) (5, 6, 7). ITSMs associate with a Src homology 2 (SH2) domain-containing protein, SLAM-associated protein (SAP; also called SH2D1A or DSHP), predominantly expressed in T and NK cells (5, 6, 7, 8, 9, 10). SAP recruits and activates the Src-family kinase Fyn through a unique SH2-SH3 domains interaction (11, 12, 13, 14). Fyn induces phosphorylation of the cytoplasmic domain of ITSM-containing receptors, allowing sequential recruitment and activation of downstream signaling adaptors and effectors such as SHIP-1, Shc, Dok1/2, and Ras-GAP. Moreover, SAP can function as a blocker, inhibiting the recruitment of protein tyrosine phosphatases like Src homology-2 phosphotyrosine phosphatase (SHP-2) to the cytoplasmic domain of ITSM-containing receptors (8, 15, 16). The importance of these SAP-mediated signaling pathways in immune responses is underscored by the observation that mutations in the SAP gene lead to X-linked lymphoproliferative syndrome (XLP), an immunodeficiency associated with dysregulated proliferation of T and B lymphocytes during primary EBV infection (5, 6, 7). An SH2 domain-containing protein similar to SAP, Ewing’s sarcoma’s/FLI1-activated transcript 2 (EAT-2) (17), has been detected in human NK cells and T cells and mouse B cells and macrophages (18, 19, 20) and shown to interact with the cytoplasmic domain of CD2-family members in transfected cells (19, 20, 21). However, EAT-2 function is poorly defined in primary cells and in vivo.

NK cells express at least three CD2 family receptors, 2B4, NTB-A, and CRACC (18, 22, 23, 24, 25, 26). 2B4 binds CD48 (27, 28); CRACC and NTB-A mediate homophilic adhesion (29, 30, 31, 32). In humans, all three of these receptors trigger NK cell-mediated cytotoxicity. Although 2B4 and NTB-A recruit SAP (15, 25), CRACC does not, despite the presence of ITSMs in its cytoplasmic domain (18). Consistent with this, analysis of NK cells from XLP patients have shown that 2B4- and NTBA-mediated cytotoxicity is SAP-dependent (25, 33, 34, 35, 36), whereas CRACC activates cytotoxicity through an ERK-mediated pathway that is SAP-independent (18). Because of the close homology between SAP and EAT-2, it is possible that CRACC recruits EAT-2 through its cytoplasmic ITSMs and that EAT-2 effectively substitutes for SAP in mediating CRACC signaling. Although we failed to detect significant association of CRACC with EAT-2 in a preliminary experiment (18), we have more thoroughly investigated the possible association of these molecules in primary human cells using a newly generated EAT-2 antiserum. In this study, we demonstrate that CRACC does indeed associate with EAT-2 in human NK cells upon ligation with a specific Ab. We show that recruitment of EAT-2 mediates the phosphorylation of CRACC, possibly by recruiting a Src kinase, and we define the signaling mediators downstream of CRACC/EAT-2 implicated in triggering NK cell-mediated cytotoxicity.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Cells and Abs

Human NK cells were purified from peripheral blood and cultured in IL-2 as previously described (37) . CD4+, CD8+, CD4+ CD8+, and {gamma} {delta} T cell clones were established from peripheral blood by limiting dilution and cultured in IL-2 as previously described (37) . Peripheral B cells and monocyte-derived dendritic cells (DC) were activated by incubation with CD40L-expressing cells and LPS, respectively. Cells lines used were: NK92 (human NK cell line that lacks the FcR CD16), P815 (murine mastocytoma), Daudi (human Burkitt lymphoma-derived B cell), 721.221 (human EBV-transformed B cell) and 293. The anti-CRACC mAbs 24 and 162 (18) and anti-2B4 mAb 2–69 (33) were generated in our laboratory. Antiserum to EAT-2 was generated by immunizing rabbits with the keyhole limpet hemocyanin-conjugated peptide DLPYYHGRLTKQDCETL. The anti-SAP Ab was a generous gift from Dr. S. G. Tangye (Centenary Institute of Cancer Medicine and Cell Biology, Newtown, New South Wales, Australia). Anti-2B4 mAb C1.7 (38) was purchased from the Immunotech laboratory, anti-phosphotyrosine 4G10 mAb was obtained from Upstate Biotechnology, and anti-Vav, anti-phospholipase C{gamma}1 (PLC {gamma} 1), anti-PLC{gamma} 2, and anti-SHIP-1 mAb were obtained from Santa Cruz Biotechnology. The pharmacological inhibitor of PLC {gamma} U73122, the inactive analog U73343 and the src kinase inhibitor PP2 were purchased from Calbiochem.

Cell stimulations and immunoprecipitations

Before stimulation with mAbs, NK92 cells (20 x 106) were cultured overnight in the absence of IL-2 to reduce confounding signals due to IL-2-mediated activation. Cells were then incubated in ice for 15 min with a saturating dose of anti-CRACC mAb 24, anti-2B4 mAb C1.7, or anti-CD56. Cells were then washed and incubated at 37°C for the indicated period of time in the presence of goat anti-mouse IgG. When indicated, cells were incubated with the src kinase inhibitor PP2 (10 µ M) or solvent (DMSO) 20 min prior to Ab stimulation as well as during Ab stimulation at 37°C. For sodium pervanadate stimulation, cells were incubated with 200 µ M sodium pervanadate for 15 min at 37°C. After stimulation, cells were lysed with lysis buffer (1% v/v Triton X-100, 50 Mm Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1.5 mM MgCl2, 10% glycerol, plus protease and phosphatase inhibitors) and immunoprecipitated with the indicated Abs. Precipitated proteins were fractionated by SDS-PAGE, transferred to nitrocellulose membranes and probed with the indicated mAb. To confirm that all substrates were adequately immunoprecipitated, immunoblots were reprobed with Abs directed against the various substrates. Because anti-CRACC Abs do not detect CRACC in immunoblotting, we ensured that each cell lysate used for CRACC immunoprecipitations contained equal amount of proteins with a control Ab (anti-EAT-2). To determine phosphorylation of AKT, cell lysates were immediately fractionated by SDS-PAGE and the active form of AKT was detected with phosphospecific Abs. Blots were reanalyzed with anti-AKT Abs to quantify proteins loaded in each lane. Anti-pAKT (Ser473) and anti-AKT Abs were obtained from New England Biolabs.

Constructs and transfections

2B4 and SAP constructs have already been described (33) . To express EAT-2 and CRACC as N-terminal FLAG fusion proteins, EAT-2 and CRACC cDNA were subcloned in pCMV2-FLAG and pCMV3-FLAG (Sigma-Aldrich), respectively. 293 cells were transiently transfected with the above plasmids using Lipofectamine 2000 (Invitrogen Life Technologies) following the manufacturer’s instructions. When described, cells were pretreated with 10 µ M PP2 (Calbiochem) for 20 min at 37°C.

Cytotoxicity assays

NK cell cytotoxicity was tested against [51Cr]-labeled P815 cells in the presence of 10 µg/ml of either mAb 162, mAb 2-69, or a control mouse IgG (Immunotech). In some experiments, NK92 cells were pretreated with the pharmacological inhibitor of PLC{gamma} U73122 (3.3 µM) or the inactive analog U73343 (3.3 µM) for 5 min at 37°C. PP2 (2 µM) or DMSO were maintained throughout the cytotoxicity assays, as PP2 effects are rapidly reversible. At the concentration used, PP2 did not affect NK cell viability, as previously reported (39).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
EAT-2 is expressed in human cytotoxic lymphocytes

EAT-2 transcripts have been detected in human CD8 and CD4 T cells (19) and in mouse B cells and macrophages (20), while EAT-2 protein has been observed in human NK cells (18). To establish the expression pattern of the EAT-2 protein in human primary leukocytes, we analyzed a variety of cell lysates by immunoblotting with a rabbit anti-human EAT-2 serum. We found abundant EAT-2 protein in NK cells, either freshly isolated from blood or after culture in IL-2, and in the NK cell lines NK92 and YT (Fig. 1A and data not shown). Moreover, we detected some EAT-2 protein in CD8+ {alpha}{beta}T cells and {gamma}{delta} T cells before and after activation with an anti-CD3 Ab (Fig. 1B). EAT-2 was absent in CD4+ T cells, CD4+CD8+ T cells (Fig. 1B), B cells (Fig. 1C), immature and LPS-activated DC (Fig. 1D). Analysis of EAT-2 expression by RT-PCR confirmed that the EAT-2 transcript was more abundant in NK cells than CD8+ and {gamma}{delta} T cells (data not shown). We conclude that EAT-2 is preferentially expressed in human cytotoxic lymphocytes, particularly NK cells.



View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 1. EAT-2 expression in human leukocytes. EAT-2 expression was assessed by immunoblot analysis of the following cell types: A, NK cells freshly isolated from human blood (NK), NK cells cultured in IL-2 (NK IL-2), the cell line NK92 and 293 cells. B, CD4+ T cells (CD4), CD8+ T cells (CD8), a CD4+CD8+ T cell clone (CD4CD8) and {gamma}{delta} T cells, either resting or stimulated with an anti-CD3 mAb. C, B cells purified from human peripheral blood and activated with CD40 ligand (B/CD40L), the Burkitt lymphoma cell line Daudi (Daudi), and the EBV-transformed B cell line 721.221 (221). D, DC either unstimulated and/or activated with LPS for 12 h (LPS 12) or 24 h (LPS 24). Each lane was loaded with a lysate of 106 cells. Fresh NK cells (NK) and the cell line 293 (293) were used as positive and negative controls, respectively.

 
CRACC associates with EAT-2 in human NK cells

Several CD2-family receptors have been shown to bind EAT-2 in transfected cell lines (19, 20, 21). To determine whether CRACC recruits EAT-2 in human NK cells, we took advantage of a well-established NK cell line NK92. We ligated CRACC on NK92 using a specific Ab and a cross-linker and analyzed CRACC immunoprecipitates from resting and CRACC-activated cells with anti-phosphotyrosine and anti-EAT-2 Abs. We observed that upon ligation, CRACC is phosphorylated and associates with EAT-2 (Fig. 2A). Analysis of CRACC immunoprecipitates with an anti-SAP Ab confirmed our previous finding that CRACC does not recruit SAP in either resting or stimulated cells (18). We also investigated association of CRACC with EAT-2 in NK92 cells stimulated with sodium pervanadate, which inhibits tyrosine phosphatases and thereby induces strong tyrosine phosphorylation of CRACC. In CRACC immunoprecipitates from pervanadate-treated cells, CRACC was associated with EAT-2 but not with SAP (Fig. 2B), consistent with our results in CRACC-stimulated NK cells. We conclude that, upon activation, CRACC selectively recruits EAT-2 in human NK cells.



View larger version (28K):
[in this window]
[in a new window]
  		FIGURE 2. CRACC associates with EAT-2, not SAP, in human NK cells; 2B4 associates with both. A, NK92 cells were stimulated for 5 min at 37°C with anti-CD56 (CTR), anti-CRACC (clone 24), or anti-2B4 (clone C1.7) mAbs. Stimulated cells were lysed and immunoprecipitated with anti-CD56 (CTR), anti-CRACC (clone 162), and anti-2B4 (clone 2-69) mAbs, respectively. Immunoprecipitates were analyzed by immunoblotting with anti-phosphotyrosine, anti-EAT-2, and anti-SAP Abs. EAT-2 is present in both CRACC and 2B4 immunoprecipitates, SAP only in the latter. Bottom panel, An immunoblot of whole cell lysates with anti-EAT-2 to control for the amount of proteins. B, NK92 cells were left untreated or stimulated with sodium pervanadate (PV). Cells were lysed and subjected to immunoprecipitation with anti-CD56 (CTR), anti-CRACC (clone 162), and anti-2B4 (clone 2-69) mAbs. Immunoprecipitates were separated on SDS-PAGE and analyzed by immunoblotting with anti-EAT-2 and anti-SAP Abs. CRACC associates exclusively with EAT-2 after activation. 2B4 associates with EAT-2 in unstimulated cells, while activation induces recruitment of SAP and reduces association with EAT-2.

 
Because the receptor 2B4 has been shown to bind EAT-2 in transfected cells (20), we determined whether this also occurs in human NK cells. In unstimulated NK92 cells, 2B4 recruited EAT-2 and exhibited a modest tyrosine phosphorylation; after Ab-mediated ligation, 2B4 association with EAT-2 was reduced, while 2B4 effectively recruited SAP, as previously reported (Ref.15 ; Fig. 2A). Consistent with this result, in pervanadate-treated cells, 2B4 association with SAP increased, while association with EAT-2 decreased (Fig. 2B). These data suggest that 2B4 can recruit both EAT-2 and SAP and that tyrosine phosphorylation of cytoplasmic ITSMs of 2B4 augments their affinity for SAP, while reducing the affinity for EAT-2.

EAT-2 mediates phosphorylation of CRACC

EAT-2 has been previously shown to induce phosphorylation of CD84, SLAM, Ly-9, and 2B4 in transfected cells (19, 20, 21). To address whether EAT-2 mediates phosphorylation of CRACC, we transiently expressed CRACC in 293 cells together with either EAT-2 or SAP, immunoprecipitated CRACC and analyzed its tyrosine phosphorylation by immunoblotting. CRACC was evidently phosphorylated in the presence of EAT-2 (Fig. 3A). 2B4 was also phosphorylated in the presence of either EAT-2 or SAP (Fig. 3B), consistent with previous reports (15, 20). To investigate whether EAT-2 induces tyrosine phosphorylation of CRACC and 2B4 by recruiting src kinases, we tested a pharmacological inhibitor of src tyrosine kinases (PP2) on EAT-2-mediated phosphorylation of CRACC and 2B4 in transfected cells. PP2 reduced CRACC and 2B4 phosphorylation (Fig. 3), suggesting that EAT-2 may induce phosphorylation by recruiting a src kinase. PP2 also reduced SAP-induced phosphorylation of 2B4, consistent with the known association of SAP with the src kinase Fyn (11, 12, 13, 14).



View larger version (16K):
[in this window]
[in a new window]
  		FIGURE 3. EAT-2 induces phosphorylation of CRACC and 2B4. 293 cells were transiently transfected with cDNAs encoding EAT-2, SAP, CRACC (all as an N-terminal FLAG-tagged fusion protein) or 2B4 in different combinations. Cells were left untreated or treated with the src-specific inhibitor PP2 (10 µM), then lysed and immunoprecipitated with anti-CRACC (clone 162) (A) or anti-2B4 (clone C1.7) mAbs (B). Immunoprecipitates were analyzed by immunoblotting with anti-phosphotyrosine ({alpha}-pTyr), or anti-SAP plus anti-EAT-2 Abs. Immunoblots with anti-FLAG and anti-2B4 were also performed to control the amounts of CRACC and 2B4 immunoprecipitates, respectively. EAT-2 induces phosphorylation of CRACC. Both EAT-2 and SAP phosphorylate 2B4. PP2 induced a partial inhibition of EAT-2-mediated phosphorylation of CRACC and 2B4 as well as SAP-mediated phosphorylation of 2B4.

 
To investigate whether EAT-2 induces CRACC phosphorylation by recruiting a src kinase in human NK cells, we investigated the effect of PP2 on CRACC phosphorylation and CRACC-mediated cytotoxicity in NK92 cells. PP2 reduced phosphorylation of CRACC induced by Ab-mediated cross-linking (Fig. 4A). In control experiments, PP2 also reduced phosphorylation of 2B4 (Fig. 4B), which has been shown to be mediated by SAP through recruitment of Fyn (40). Thus, results suggests that EAT-2-induced phosphorylation of CRACC may involve a src kinase. In support of this hypothesis, we also observed that PP2 potently inhibited CRACC- and 2B4-mediated redirected lysis of P815, whereas the PP2 solvent DMSO did not (Fig. 4C). It has been reported that EAT-2 induces tyrosine phosphorylation of associated receptors by blocking their ability to recruit protein tyrosine phosphatases, particularly SHP-2 (20). However, we detected no association of CRACC with SHP-1, SHP-2, or SHIP-1 in resting or Ab-stimulated NK92 cells (data not shown). Thus, although in transfected cells EAT-2 may induce CRACC phosphorylation by interfering with CRACC-SHP-2 association, this is unlikely to be a crucial mechanism in human NK cells.



View larger version (55K):
[in this window]
[in a new window]
  		FIGURE 4. PP2 inhibits CRACC phosphorylation and CRACC-mediated cytotoxicity in NK92 cells. A and B, NK92 cells were treated with the src kinase-specific inhibitor PP2 or the PP2 solvent (DMSO) alone and stimulated for 5 min (5') at 37°C with anti-CRACC (clone 24) or anti-2B4 (clone C1.7) mAbs. Stimulated cells were lysed and immunoprecipitated with anti-CRACC (clone 162) and anti-2B4 (clone 2-69) mAbs, respectively. Immunoprecipitates were analyzed by immunoblotting with an anti-phosphotyrosine mAb. Bottom panels, Immunoblots of whole cell lysates with anti-EAT-2 to control for amount of proteins. C, NK92 cells were incubated with 2 µM PP2 or DMSO and assayed for their cytotoxicity against [51Cr]-labeled P815 cells in the presence of anti-CRACC, anti-2B4, or a control Ab.

 
Ligation of CRACC induces the activation of PLC{gamma} and PI3K signaling pathways

To identify downstream mediators that become activated in response to ligation of CRACC, we cross-linked CRACC on NK92 cells and analyzed several downstream effectors by immunoprecipitation and anti-phosphotyrosine immunoblotting. Ligation of CRACC induced phosphorylation of PLC{gamma}1 and PLC{gamma}2 (Fig. 5, A and B). Moreover, we detected a significant phosphorylation of Akt, which is an indicator of PI3K activation (Fig. 5C), and the E3 ubiquitin ligase c-Cbl (Fig. 5D). Ligation of CRACC induced modest tyrosine phosphorylation of the guanine nucleotide exchange factors Vav and the 5' inositol phosphatase SHIP-1 (Fig. 5, E and F). No phosphorylation of Shc and LAT was observed (data not shown). In comparison with CRACC-mediated activation, ligation of 2B4 was as effective in phosphorylating PLC{gamma}1, PLC{gamma}2, Akt, and c-Cbl and more effective in activating Vav and SHIP-1. Although two studies have shown that LAT is constitutively associated with 2B4 (41, 42), we detected no phosphorylation of LAT (data not shown). Moreover, we observed no 2B4-mediated phosphorylation of Shc. Collectively, these results suggest that PLC{gamma}1, PLC{gamma}2, PI3K, and c-Cbl are the major substrates involved in downstream signaling events initiated by CRACC. Moreover, our data indicate that, despite differential recruitment of EAT-2 and SAP, CRACC and 2B4 activate similar signaling adaptor and effector molecules.



View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 5. Identification of substrates that are tyrosine-phosphorylated in response to CRACC ligation. NK92 cells were left unstimulated or stimulated with anti-CRACC (clone 24), anti-2B4 (clone C1.7), or anti-CD56 (CTR) mAbs. Cell lysates were then immunoprecipitated with anti-PLC{gamma}1 (A), anti-PLC{gamma}2 (B), anti-c-Cbl (D), anti-SHIP-1 (E), anti-Vav (F) Abs. Tyrosine phosphorylation was assessed by immunoblotting with anti-phosphotyrosine Ab. To confirm that all substrates were adequately immunoprecipitated, immunoblots were reprobed with Abs directed against the various substrates. Phosphorylation of AKT (C) was detected by immunoblotting whole cell lysates with anti-pAKT Ab. The same membrane was stripped and reprobed with anti-AKT Ab.

 
To substantiate the implication that activation of PLC{gamma}1 and PLC{gamma}2 is critical for CRACC- and 2B4-mediated cytotoxicity, we determined whether this function could be inhibited by the pharmacological PLC{gamma} inhibitor U73122. NK92 cells effectively killed the FcR bearing P815 cell in the presence of anti-CRACC or anti-2B4 Abs (Fig. 6). U73122 potently inhibited CRACC- and 2B4-mediated redirected lysis of P815, whereas the pharmacologically inactive analog U73343 did not (Fig. 6), confirming a role for PLC{gamma} in CRACC- and 2B4-mediated cytotoxicity.



View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 6. A pharmacological inhibitor of PLC{gamma} blocks CRACC-mediated cytotoxicity. NK92 cells were incubated for 5 min at 37°C with the PLC{gamma} inhibitor U73122, its inactive analog U73343 or DMSO as control, and assayed as cytotoxic effectors against [51Cr]-labeled P815 cells in the presence of anti-CRACC and anti-2B4 mAb.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
Our results provide the first demonstration that CRACC recruits EAT-2 in NK cells. We previously showed that CRACC is a unique CD2-family receptor in that it triggers cytotoxicity independently of SAP, despite the presence of ITSMs in its cytoplasmic domain (18). As EAT-2 is closely related to SAP, we hypothesized that CRACC may trigger cytotoxicity through EAT-2. Although we were not able to detect significant association of CRACC with EAT-2 in a preliminary experiment (18), using a newly generated anti-EAT-2 antiserum we now provide conclusive evidence that CRACC recruits EAT-2 after Ab-mediated cross-linking in NK cells. We also show that EAT-2 protein is preferentially expressed in primary NK cells, CD8+ T cells, and {gamma}{delta} T cells, whereas we detect no EAT-2 protein in CD4+ T cells, CD4+CD8+ T cells, B cells, and DC. Yet, CRACC is expressed in CD4+ T cells, B cells and DC as well as NK cells and CD8+ T cells, suggesting that CRACC signaling differs in distinct cell types. Moreover, as EAT-2 transcripts have been detected in murine B cells and macrophages, our data provide evidence for a significant difference in the cellular distribution of human and mouse EAT-2.

We show that 2B4 also recruits EAT-2 in NK cells, consistent with a previous report showing that 2B4 and other CD2-family receptors associate with EAT-2 in transfected cells (19, 20, 21). Because 2B4 associates with SAP, this observation raises the question of whether SAP and EAT-2 compete for binding to 2B4 or associate independently of one another (19) and whether SAP and EAT-2 play redundant roles. We observed that EAT-2 preferentially binds 2B4 in nonactivated cells, whereas SAP binds better after cell activation. Thus, it is possible that EAT-2 and SAP compete for one or more cytoplasmic ITSMs of 2B4 and that ITSM phosphorylation following activation favors recruitment of SAP over EAT-2. Interestingly, in SAP-deficient NK cells from XLP patients, 2B4 is no longer capable of triggering cytotoxicity (25, 33, 34, 35, 36), despite the presence of EAT-2. Thus, SAP and EAT-2 appear to play nonredundant roles in 2B4 signaling and function.

Although in our study, EAT-2 promotes CRACC and 2B4 phosphorylation, recently, Roncagalli et al. (43) showed that EAT-2 is a negative regulator of mouse NK cell function and phosphorylation. Moreover, they demonstrated that this inhibitory function depends on two C-terminal tyrosines of EAT-2. However, because human EAT-2 lacks one of these tyrosines, it may be devoid of inhibitory functions.

In this report, we found that EAT-2 induces tyrosine phosphorylation of CRACC. Two mechanisms may be involved in this phenomenon. EAT-2 may recruit a src kinase, as SAP does (11, 12, 13, 14). Supporting this mechanism, the inhibitor of src kinases PP2 reduced EAT-2-induced phosphorylation of CRACC or 2B4 in transfected cells. Moreover, PP2 inhibited Ab-mediated CRACC phosphorylation and CRACC-induced cytotoxicity in human NK cells. Although we were unable to detect association of Fyn or other src kinases with CRACC (data not shown), it is possible that the binding affinity of EAT-2 for src kinases is too low to be detected in immunoprecipitation experiments. Surface plasmon resonance studies are required to conclusively assess the binding of soluble EAT-2 SH2 domain to soluble SH3 domains of various src kinases. Another mechanism for EAT-2-induced phosphorylation may rely on the ability of EAT-2 to block the recruitment of protein tyrosine phosphatases. It was previously shown that several CD2-family receptors associate with SHP-2 in transfected cells, and that this association is reduced by EAT-2 (20). However, we were unable to detect association of CRACC with SHP-2 or other phosphatases in resting NK cells as well as after Ab-mediated stimulation, when CRACC is phosphorylated and recruits more EAT-2. Thus, EAT-2-mediated blockade of protein tyrosine phosphatases recruitment does not appear to be a crucial mechanism in inducing phosphorylation of CRACC in human NK cells.

We provide biochemical demonstration that CRACC activates PLC{gamma}1, PLC{gamma}2, and PI3K. These intracellular signaling molecules are likely to be major intermediates in CRACC-induced NK cell activation and cytotoxicity. Critical involvement of PLC{gamma}1 and PLC{gamma}2 in CRACC-mediated cytotoxicity is corroborated by blocking of CRACC-mediated cytotoxicity in the presence of a pharmacological inhibitor of PLC{gamma}. Moreover, activation of PLC{gamma}1 and PLC{gamma}2 is most likely responsible for the intracellular Ca2+ flux mediated by CRACC in a transfected NK cell line (44). PI3K may trigger CRACC-mediated cytotoxicity by generating phosphatidylinositol 3,4,5 trisphosphate (PIP3), which is essential for membrane recruitment and activation of PLC{gamma}1 and PLC{gamma}2. Moreover, it has been shown that PI3K can activate the NK cytolytic machinery by inducing sequential activation of the GTP-binding-protein Rac1, the cytoplasmic kinases Pak1 and MEK, and ERK1/2 (45). Our previous demonstration that pharmacological inhibitors of ERK block CRACC-mediated cytotoxicity suggests that this pathway may be involved (18). Ligation of CRACC also induced phosphorylation of c-Cbl and, to a minor extent, of Vav and SHIP-1. Whether these effectors are critical in regulating CRACC-mediated cytotoxicity remains to be determined.

Interestingly, despite differential recruitment of EAT-2 and SAP, CRACC and 2B4 activated a remarkably similar spectrum of downstream effectors triggering cytotoxicity. We found that ligation of 2B4 induces activation of PLC{gamma}1 and PLC{gamma}2. Although phosphorylation of PLC{gamma}1 was not reported in a previous study (40), these experiments were performed in the NK cell line YT, which differs significantly from the NK92 cell line used in our study in that it does not require IL-2 for expansion. 2B4-mediated phosphorylation of PI3K, Vav1, c-Cbl, and SHIP-1 has been corroborated in previous studies (40, 46). Although 2B4 has been reported to constitutively bind the adaptor protein LAT (41, 42), like Chen et al. (40), we were unable to detect phosphorylation of LAT. These discrepancies in detecting 2B4-LAT associations and/or LAT phosphorylation may be due to the use of different detergents or cell lines.

In conclusion, we have shown that the natural cytotoxicity receptor CRACC is unique among CD2-family receptors in that it recruits the adaptor EAT-2 but not SAP in human NK cells after activation. EAT-2 induces phosphorylation of CRACC, possibly by recruiting a src-family kinase to the cytoplasmic domain of CRACC. Upon ligation and phosphorylation, CRACC activates downstream effectors of cytotoxicity, including PLC{gamma} and PI3K. These results outline a new signaling pathway leading to NK cell-mediated cytotoxicity.


   Acknowledgments
 
We thank Susan Gilfillan for reading the manuscript and Marina Cella for helpful advice throughout the experiments.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by National Institutes of Health Grant No. 5R01AI056139-03. Back

2 Address correspondence and reprint requests to Dr. Marco Colonna, Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110. E-mail address: mcolonna{at}pathbox.wustl.edu Back

3 Abbreviations used in this paper: SLAM, signaling lymphocytic activation molecule; NTB-A, NK-T-B-Ag; CRACC, CD2-like receptor-activating cytotoxic cell; BLAME, B lymphocyte activator macrophage expressed; ITSM, immunoreceptor tyrosine-based switch motif; SH, Src homology; SAP, SLAM-associated protein; XLP, X-linked lymphoproliferative syndrome; EAT-2, Ewing’s sarcoma’s/FLI1-activated transcript 2; DC, dendritic cell; PLC{gamma}, phospholipase C{gamma}; SHP, SH-2 phosphotyrosine phosphatase. Back

Received for publication May 17, 2005. Accepted for publication September 29, 2005.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Lanier, L. L.. 2005. NK cell recognition. Annu. Rev. Immunol. 23: 225-274. [Medline]
  2. Vivier, E., J. A. Nunes, F. Vely. 2004. Natural killer cell signaling pathways. Science 306: 1517-1519. [Abstract/Free Full Text]
  3. Colucci, F., J. P. Di Santo, P. J. Leibson. 2002. Natural killer cell activation in mice and men: different triggers for similar weapons?. Nat. Immunol. 3: 807-813. [Medline]
  4. Perussia, B.. 2000. Signaling for cytotoxicity. Nat. Immunol. 1: 372-374. [Medline]
  5. Nichols, K. E., C. S. Ma, J. L. Cannons, P. L. Schwartzberg, S. G. Tangye. 2005. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol. Rev. 203: 180-199. [Medline]
  6. Latour, S., A. Veillette. 2004. The SAP family of adaptors in immune regulation. Semin. Immunol. 16: 409-419. [Medline]
  7. Engel, P., M. J. Eck, C. Terhorst. 2003. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat. Rev. Immunol. 3: 813-821. [Medline]
  8. Sayos, J., C. Wu, M. Morra, N. Wang, X. Zhang, D. Allen, S. van Schaik, L. Notarangelo, R. Geha, M. G. Roncarolo, et al 1998. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 395: 462-469. [Medline]
  9. Coffey, A. J., R. A. Brooksbank, O. Brandau, T. Oohashi, G. R. Howell, J. M. Bye, A. P. Cahn, J. Durham, P. Heath, P. Wray, et al 1998. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat. Genet. 20: 129-135. [Medline]
  10. Nichols, K. E., D. P. Harkin, S. Levitz, M. Krainer, K. A. Kolquist, C. Genovese, A. Bernard, M. Ferguson, L. Zuo, E. Snyder, et al 1998. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc. Natl. Acad. Sci. USA 95: 13765-13770. [Abstract/Free Full Text]
  11. Davidson, D., X. Shi, S. Zhang, H. Wang, M. Nemer, N. Ono, S. Ohno, Y. Yanagi, A. Veillette. 2004. Genetic evidence linking SAP, the X-linked lymphoproliferative gene product, to Src-related kinase FynT in Th2 cytokine regulation. Immunity 21: 707-717. [Medline]
  12. Latour, S., R. Roncagalli, R. Chen, M. Bakinowski, X. Shi, P. L. Schwartzberg, D. Davidson, A. Veillette. 2003. Binding of SAP SH2 domain to FynT SH3 domain reveals a novel mechanism of receptor signalling in immune regulation. Nat. Cell Biol. 5: 149-154. [Medline]
  13. Chan, B., A. Lanyi, H. K. Song, J. Griesbach, M. Simarro-Grande, F. Poy, D. Howie, J. Sumegi, C. Terhorst, M. J. Eck. 2003. SAP couples Fyn to SLAM immune receptors. Nat. Cell Biol. 5: 155-160. [Medline]
  14. Latour, S., G. Gish, C. D. Helgason, R. K. Humphries, T. Pawson, A. Veillette. 2001. Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat. Immunol. 2: 681-690. [Medline]
  15. Tangye, S. G., S. Lazetic, E. Woollatt, G. R. Sutherland, L. L. Lanier, J. H. Phillips. 1999. Cutting edge: human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. J. Immunol. 162: 6981-6985. [Abstract/Free Full Text]
  16. Eissmann, P., L. Beauchamp, J. Wooters, J. C. Tilton, E. O. Long, C. Watzl. 2005. Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). Blood 105: 4722-4729. [Abstract/Free Full Text]
  17. Thompson, A. D., B. S. Braun, A. Arvand, S. D. Stewart, W. A. May, E. Chen, J. Korenberg, C. Denny. 1996. EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing’s sarcoma EWS/FLI1 fusion gene. Oncogene 13: 2649-2658. [Medline]
  18. Bouchon, A., M. Cella, H. L. Grierson, J. I. Cohen, M. Colonna. 2001. Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J. Immunol. 167: 5517-5521. [Abstract/Free Full Text]
  19. Tangye, S. G., K. E. Nichols, N. J. Hare, B. C. van de Weerdt. 2003. Functional requirements for interactions between CD84 and Src homology 2 domain-containing proteins and their contribution to human T cell activation. J. Immunol. 171: 2485-2495. [Abstract/Free Full Text]
  20. Morra, M., J. Lu, F. Poy, M. Martin, J. Sayos, S. Calpe, C. Gullo, D. Howie, S. Rietdijk, A. Thompson, et al 2001. Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells. EMBO J. 20: 5840-5852. [Medline]
  21. Tangye, S. G., B. C. van de Weerdt, D. T. Avery, P. D. Hodgkin. 2002. CD84 is up-regulated on a major population of human memory B cells and recruits the SH2 domain containing proteins SAP and EAT-2. Eur. J. Immunol. 32: 1640-1649. [Medline]
  22. Kumar, V., M. E. McNerney. 2005. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat. Rev. Immunol. 5: 363-374. [Medline]
  23. Boles, K. S., S. E. Stepp, M. Bennett, V. Kumar, P. A. Mathew. 2001. 2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes. Immunol. Rev. 181: 234-249. [Medline]
  24. Mathew, P. A., B. A. Garni-Wagner, K. Land, A. Takashima, E. Stoneman, M. Bennett, V. Kumar. 1993. Cloning and characterization of the 2B4 gene encoding a molecule associated with non-MHC-restricted killing mediated by activated natural killer cells and T cells. J. Immunol. 151: 5328-5337. [Abstract]
  25. Bottino, C., M. Falco, S. Parolini, E. Marcenaro, R. Augugliaro, S. Sivori, E. Landi, R. Biassoni, L. D. Notarangelo, L. Moretta, A. Moretta. 2001. NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. J. Exp. Med. 194: 235-246. [Abstract/Free Full Text]
  26. Boles, K. S., P. A. Mathew. 2001. Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily. Immunogenetics 52: 302-307. [Medline]
  27. Brown, M. H., K. Boles, P. A. van der Merwe, V. Kumar, P. A. Mathew, A. N. Barclay. 1998. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J. Exp. Med. 188: 2083-2090. [Abstract/Free Full Text]
  28. Kubin, M. Z., D. L. Parshley, W. Din, J. Y. Waugh, T. Davis-Smith, C. A. Smith, B. M. Macduff, R. J. Armitage, W. Chin, L. Cassiano, et al 1999. Molecular cloning and biological characterization of NK cell activation-inducing ligand, a counterstructure for CD48. Eur. J. Immunol. 29: 3466-3477. [Medline]
  29. Murphy, J. J., P. Hobby, J. Vilarino-Varela, B. Bishop, P. Iordanidou, B. J. Sutton, J. D. Norton. 2002. A novel immunoglobulin superfamily receptor (19A) related to CD2 is expressed on activated lymphocytes and promotes homotypic B-cell adhesion. Biochem. J. 361: 431-436. [Medline]
  30. Kumaresan, P. R., W. C. Lai, S. S. Chuang, M. Bennett, P. A. Mathew. 2002. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol. Immunol. 39: 1-8. [Medline]
  31. Flaig, R. M., S. Stark, C. Watzl. 2004. Cutting edge: NTB-A activates NK cells via homophilic interaction. J. Immunol. 172: 6524-6527. [Abstract/Free Full Text]
  32. Falco, M., E. Marcenaro, E. Romeo, F. Bellora, D. Marras, F. Vely, G. Ferracci, L. Moretta, A. Moretta, C. Bottino. 2004. Homophilic interaction of NTBA, a member of the CD2 molecular family: induction of cytotoxicity and cytokine release in human NK cells. Eur. J. Immunol. 34: 1663-1672. [Medline]
  33. Nakajima, H., M. Cella, A. Bouchon, H. L. Grierson, J. Lewis, C. S. Duckett, J. I. Cohen, M. Colonna. 2000. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur. J. Immunol. 30: 3309-3318. [Medline]
  34. Tangye, S. G., J. H. Phillips, L. L. Lanier, K. E. Nichols. 2000. Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. J. Immunol. 165: 2932-2936. [Abstract/Free Full Text]
  35. Benoit, L., X. Wang, H. F. Pabst, J. Dutz, R. Tan. 2000. Defective NK cell activation in X-linked lymphoproliferative disease. J. Immunol. 165: 3549-3553. [Abstract/Free Full Text]
  36. Parolini, S., C. Bottino, M. Falco, R. Augugliaro, S. Giliani, R. Franceschini, H. D. Ochs, H. Wolf, J. Y. Bonnefoy, R. Biassoni, et al 2000. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J. Exp. Med. 192: 337-346. [Abstract/Free Full Text]
  37. Cella, M., M. Colonna. 2000. Cloning human natural killer cells. Methods Mol. Biol. 121: 1-4. [Medline]
  38. Valiante, N. M., G. Trinchieri. 1993. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. J. Exp. Med. 178: 1397-1406. [Abstract/Free Full Text]
  39. Pisegna, S., A. Zingoni, G. Pirozzi, B. Cinque, M. G. Cifone, S. Morrone, M. Piccoli, L. Frati, G. Palmieri, A. Santoni. 2002. Src-dependent Syk activation controls CD69-mediated signaling and function on human NK cells. J. Immunol. 169: 68-74. [Abstract/Free Full Text]
  40. Chen, R., F. Relouzat, R. Roncagalli, A. Aoukaty, R. Tan, S. Latour, A. Veillette. 2004. Molecular dissection of 2B4 signaling: implications for signal transduction by SLAM-related receptors. Mol. Cell Biol. 24: 5144-5156. [Abstract/Free Full Text]
  41. Bottino, C., R. Augugliaro, R. Castriconi, M. Nanni, R. Biassoni, L. Moretta, A. Moretta. 2000. Analysis of the molecular mechanism involved in 2B4-mediated NK cell activation: evidence that human 2B4 is physically and functionally associated with the linker for activation of T cells. Eur. J. Immunol. 30: 3718-3722. [Medline]
  42. Klem, J., P. C. Verrett, V. Kumar, J. D. Schatzle. 2002. 2B4 is constitutively associated with linker for the activation of T cells in glycolipid-enriched microdomains: properties required for 2B4 lytic function. J. Immunol. 169: 55-62. [Abstract/Free Full Text]
  43. Roncagalli, R., J. E. Taylor, S. Zhang, X. Shi, R. Chen, M. E. Cruz-Munoz, L. Yin, S. Latour, A. Veillette. 2005. Negative regulation of natural killer cell function by EAT-2, a SAP-related adaptor. Nat. Immunol. 6: 1002-1010. [Medline]
  44. Lee, J. K., K. S. Boles, P. A. Mathew. 2004. Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs. Eur. J. Immunol. 34: 2791-2799. [Medline]
  45. Jiang, K., B. Zhong, D. L. Gilvary, B. C. Corliss, E. Hong-Geller, S. Wei, J. Y. Djeu. 2000. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat. Immunol. 1: 419-425. [Medline]
  46. Aoukaty, A., R. Tan. 2002. Association of the X-linked lymphoproliferative disease gene product SAP/SH2D1A with 2B4, a natural killer cell-activating molecule, is dependent on phosphoinositide 3-kinase. J. Biol. Chem. 277: 13331-13337. [Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
N. G. Clarkson and M. H. Brown
Inhibition and Activation by CD244 Depends on CD2 and Phospholipase C-{gamma}1
J. Biol. Chem., September 11, 2009; 284(37): 24725 - 24734.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y.-T. Tai, E. Soydan, W. Song, M. Fulciniti, K. Kim, F. Hong, X.-F. Li, P. Burger, M. J. Rumizen, S. Nahar, et al.
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells
Blood, April 30, 2009; 113(18): 4309 - 4318.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Giustiniani, A. Bensussan, and A. Marie-Cardine
Identification and Characterization of a Transmembrane Isoform of CD160 (CD160-TM), a Unique Activating Receptor Selectively Expressed upon Human NK Cell Activation
J. Immunol., January 1, 2009; 182(1): 63 - 71.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Kamperschroer, D. M. Roberts, Y. Zhang, N.-p. Weng, and S. L. Swain
SAP Enables T Cells to Help B Cells by a Mechanism Distinct from Th Cell Programming or CD40 Ligand Regulation
J. Immunol., September 15, 2008; 181(6): 3994 - 4003.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Micucci, C. Capuano, E. Marchetti, M. Piccoli, L. Frati, A. Santoni, and R. Galandrini
PI5KI-dependent signals are critical regulators of the cytolytic secretory pathway
Blood, April 15, 2008; 111(8): 4165 - 4172.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. K. Lee, S. O. Mathew, S. V. Vaidya, P. R. Kumaresan, and P. A. Mathew
CS1 (CRACC, CD319) Induces Proliferation and Autocrine Cytokine Expression on Human B Lymphocytes
J. Immunol., October 1, 2007; 179(7): 4672 - 4678.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. G. Clarkson, S. J. Simmonds, M. J. Puklavec, and M. H. Brown
Direct and Indirect Interactions of the Cytoplasmic Region of CD244 (2B4) in Mice and Humans with FYN Kinase
J. Biol. Chem., August 31, 2007; 282(35): 25385 - 25394.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Eissmann and C. Watzl
Molecular Analysis of NTB-A Signaling: A Role for EAT-2 in NTB-A-Mediated Activation of Human NK Cells.
J. Immunol., September 1, 2006; 177(5): 3170 - 3177.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. A. Wahle, K. H. T. Paraiso, A. L. Costello, E. L. Goll, C. L. Sentman, and W. G. Kerr
Cutting Edge: Dominance by an MHC-Independent Inhibitory Receptor Compromises NK Killing of Complex Targets.
J. Immunol., June 15, 2006; 176(12): 7165 - 7169.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tassi, I.
Right arrow Articles by Colonna, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tassi, I.
Right arrow Articles by Colonna, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS